Swiss National Bank boosted its position in Flexion Therapeutics Inc (NASDAQ:FLXN) by 33.4% during the 4th quarter, Holdings Channel reports. The fund owned 47,911 shares of the specialty pharmaceutical company’s stock after buying an additional 12,000 shares during the quarter. Swiss National Bank’s holdings in Flexion Therapeutics were worth $1,200,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Teacher Retirement System of Texas bought a new position in Flexion Therapeutics in the fourth quarter valued at about $245,000. Alps Advisors Inc. boosted its holdings in Flexion Therapeutics by 32.4% in the fourth quarter. Alps Advisors Inc. now owns 41,599 shares of the specialty pharmaceutical company’s stock valued at $1,042,000 after acquiring an additional 10,176 shares during the last quarter. American Century Companies Inc. boosted its holdings in Flexion Therapeutics by 6.9% in the fourth quarter. American Century Companies Inc. now owns 115,509 shares of the specialty pharmaceutical company’s stock valued at $2,892,000 after acquiring an additional 7,483 shares during the last quarter. Perkins Capital Management Inc. bought a new position in Flexion Therapeutics in the fourth quarter valued at about $1,340,000. Finally, Legato Capital Management LLC bought a new position in Flexion Therapeutics in the fourth quarter valued at about $447,000. Institutional investors and hedge funds own 94.71% of the company’s stock.

How to Become a New Pot Stock Millionaire

Flexion Therapeutics Inc (NASDAQ:FLXN) opened at $27.06 on Wednesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 13.02 and a quick ratio of 12.96. Flexion Therapeutics Inc has a 1-year low of $16.51 and a 1-year high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last issued its earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.11) by ($0.27). The business had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $1.29 million. research analysts predict that Flexion Therapeutics Inc will post -4.89 earnings per share for the current year.

Several research firms recently issued reports on FLXN. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price target (down previously from $37.00) on shares of Flexion Therapeutics in a report on Friday, March 9th. Zacks Investment Research upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. BidaskClub upgraded Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 28th. ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 5th. Finally, Berenberg Bank started coverage on Flexion Therapeutics in a report on Thursday, February 1st. They set a “buy” rating and a $42.00 target price on the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. Flexion Therapeutics currently has an average rating of “Buy” and a consensus target price of $99.00.

TRADEMARK VIOLATION NOTICE: This news story was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2018/03/14/swiss-national-bank-purchases-12000-shares-of-flexion-therapeutics-inc-flxn.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.